Cancer Core Europe Members
Going beyond borders to unite innovative centers of excellence is Cancer Core Europe’s vision: to effectively translate research progress to the clinic for the benefit of patients.
Cancer Core Europe brings together the expertise and critical mass required to effectively move translational research into the clinic, bringing breakthrough discoveries to benefit patients at an appropriate cost. Providing an environment where basic, translational, and clinical research occur side-by-side in our centers means that patients can benefit directly from experimental findings. Likewise, observations made in the clinic inform research being carried out. Cancer Core Europe, with the support of patient advocates, embraces this patient-centered approach. Sharing is essential—the complementary expertise of each center will sustain a common infrastructure providing patients with access to cutting-edge therapies, targeted for each patient and including immune therapies. Collective efforts to pool information from clinical, environmental, genomic, imaging and immune biology databases, will transform clinicians’ and researchers’ approach to cancer research, thereby permitting a deeper understanding than any single center could achieve on its own. Dissemination of findings to the public and specialists and training the future generation of oncologists will contribute to improving cancer health in Europe.
Cancer Research UK Cambridge Centre
COMMITTED TO DELIVERING CAMBRIDGE’S VISION FOR CANCER PREVENTION, EARLY DIAGNOSIS, TREATMENT & MONITORING I.E. TO REDUCE THE MORBIDITY AND MORTALITY OF PATIENTS WITH CANCER THROUGH RESEARCH, TREATMENT AND EDUCATION
Under the umbrella of the Cancer Research UK Cambridge Centre - a dynamic collaboration of researchers, clinicians and the pharmaceutical and biotech industries based in the Cambridge area including:
the School of Clinical Medicine of the University of Cambridge - the second highest ranked university in the world
the teaching hospitals of the University of Cambridge – Cambridge University Hospitals NHS Foundation Trust (Addenbrooke’s and the Rosie) and Papworth Hospital NHS Foundation Trust
the Medical Research Council Laboratory of Molecular Biology - associated with 14 Nobel Prize winners
the Cambridge Biomedical Research Centre –a partnership between Cambridge University Hospitals Foundation Trust (the teaching hospitals of the University of Cambridge ) and the University of Cambridge; awarded a 5-year grant in 2012 of over £110m for translational research with cancer as one of the main research themes
the UK’s top 2 pharma companies - AstraZeneca’s largest centre for oncology research worldwide (due to open in 2018) and GSK’s Clinical Unit
the headquarters of the UK’s Precision Medicine Catapult with a focus on cancer
German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT)
THE NATIONAL CENTER FOR TUMOR DISEASES – NCT HEIDELBERG WAS FOUNDED AS AN EXCEPTIONAL ALLIANCE BETWEEN THE GERMAN CANCER RESEARCH CENTER (DKFZ), HEIDELBERG UNIVERSITY HOSPITAL (UKHD), THE HEIDELBERG MEDICAL FACULTY, AND GERMAN CANCER AID (DEUTSCHE KREBSHILFE)
The German Cancer Research Center (DKFZ) is the largest biomedical research center in Germany (staff: 3000). Established in 1964, DKFZ pursues the mission to unravel cancer causes and mechanisms. In addition to its excellence in basic science, DKFZ has a track record of outstanding translational research, since 2005 consolidated into its dedicated clinical translation center - the National Center for Tumor Diseases (NCT) - in collaboration with the Heidelberg University Hospital together with the Heidelberg Medical Faculty and German Cancer Aid (Deutsche Krebshilfe).
The NCT provides infrastructure and resources that integrate and support all of DKFZ’s and HUMS’s clinical and translational cancer research activities. DKFZ provides NCT with full access to its excellent research infrastructure and resources.Established in 1964, DKFZ is the largest biomedical research center in Germany (staff: 3000). Research activities concentrate on basic cancer research, disease modeling, and translational cancer research. DKFZ is an international leader in the areas of brain tumors, genome-based molecular stratification, and innovative radiation oncology. UKHD is one of the largest and most prestigious medical centers in Europe (11,768 staff). The highest standards of medical care are guaranteed by world-renowned professors, distinguished physicians and committed nursing staff. Heidelberg University Hospital is constantly developing new methods of diagnosis and treatment at the forefront of biomedical science for the benefit of all patients. AT NCT patient numbers are steadily growing and various therapeutic and preventive clinical trials, including investigator initiated trials, are developed and conducted.
GUSTAVE ROUSSY ASSEMBLES THE SKILLS NEEDED TO CARRY OUT HIGH-CALIBER ONCOLOGY RESEARCH, INTEGRATING FUNDAMENTAL, CLINICAL, AND TRANSLATIONAL RESEARCH—THEREBY ENSURING THAT THE CONTINUUM BETWEEN RESEARCH AND CARE HERALDS THERAPEUTIC ADVANCES AND IMPROVEMENTS IN PATIENT DIAGNOSIS
Gustave Roussy is France's largest cancer center, an international referral center for oncology, and an integrated center for patient care, research, and teaching that has been labeled a Comprehensive Cancer Center by the French National Cancer Institute, INCa (Institut National du Cancer).
Gustave Roussy’s Development Plan for 2015-2020 provides a framework for a new cancer center model to create a center of expertise that is equipped with cutting-edge technology platforms meeting the challenges of molecular medicine and immunotherapy through research and development of early testing techniques. In pursuit of its ambition to provide comprehensive care that is focused on the individual, Gustave Roussy will combine these cutting-edge technologies with a more customized approach to take patient preferences into account. Gustave Roussy is defined by its compassion, commitment, creativity, dynamism and willingness to share its expertise--all for the benefit of patients.
Every day at Gustave Roussy, cutting-edge research produces major advances to improve patient treatment. Our key mission is to innovate and increase access to innovative therapies for our patients.
From fundamental research to technological innovation; from epidemiology to clinical trials; and from sociology to psycho-oncology: Gustave Roussy marshals all the skills which are essential to speed up discoveries in the field of oncology. This broad range of expertise is reflected the integrated research policy which brings together fundamental, translational, and clinical research, together with clinical practice. Armed with an entrepreneurial spirit, our researchers, clinicians, and caregivers are dedicated to making innovative discoveries that directly benefit patients’ lives.
Istituto Nazionale dei Tumori di Milano
THE NATIONAL TUMOR INSTITUTE OF MILAN (INT), FOUNDATION AND GOVERNMENT-DESIGNATED CENTRE FOR TREATMENT AND RESEARCH (IRCCS), IS A LEADING CANCER CENTER IN ITALY PURSUING MAINLY CLINICAL AND TRANSLATIONAL RESEARCH, EXPLORING AND DEVELOPING THE FIELDS OF BIOMEDICINE AND PUBLIC HEALTH, IN ORDER TO DELIVER HIGH QUALITY HEALTHCARE SERVICES
The National Tumor Institute in Milan (hereafter, “INT”) was established in 1928 and became a public IRCCS Foundation in 2006. A recognized Comprehensive Cancer Center (CCC) since 2013, INT conducts translational and bidirectional research, moving from basic research, healthcare needs, epidemiology, clinical results and biobanks, and back to basic research. INT counts a total of 2.104 employees, of which 1.372 are healthcare personnel and 363 administrative personnel.
INT has recently been designated a Comprehensive Cancer Centre by the Organization of European Cancer Institute (OECI) in recognition of its excellence both in patient care and the development of new treatments.
INT research aims to improve prevention, early diagnosis and treatment of cancer diseases, and the quality of life of cancer patients. Research activity is based on integration and synergy between: preclinical and basic research, translational research, clinical research and epidemiological research.
KAROLINSKA INSTITUTET (KI) IS A COMPREHENSIVE MEDICAL UNIVERSITY COVERING BIOMEDICAL, CLINICAL, EPIDEMIOLOGICAL AND NURSING RESEARCH IN VIRTUALLY ALL MEDICAL DISCIPLINES. CANCER CENTER KAROLINSKA IS A TRANSLATIONAL CANCER RESEARCH STRUCTURE LINKED TO THE ONCOLOGY CLINIC WHERE 29 RESEARCH GROUPS HAVE THEIR LABORATORIES THAT SPAN PRECLINICAL TO CLINICAL RESEARCH0
Karolinska Institutet has 7000 students in undergraduate programs and 2200 in postdoctoral programs and consists of 22 departments, 6 in basic biomedicine and the rest at the clinic. The clinical part of research and training is the Karolinska University Hospital, which has two sites (the former Karolinska Hospital northern site, and Huddinge Hospital southern site) including collaboration with three community hospitals. A new hospital building, New Karolinska Solna, is gradually employed during 2017 and 2018. Basic preclinical research is located at the Karolinska Institutet Campus and some institutions at the Huddinge site. Clinical research regarding solid tumors and paediatric oncology is located at the northern site. Haematology is represented at both University Hospital sites. Overall, Karolinska Institutet has 16 programs to train medical and paramedical staff; apart from medicine and odontology, this also includes nursing, physiotherapy, biomedicine, toxicology, as well as other disciplines. Altogether 140 research groups with more than 800 members in twelve of the twenty-two departments are active in cancer research.
Netherlands Cancer Institute
NKI ACTIVELY STIMULATES COLLABORATION BETWEEN CLINICAL AND BASIC SCIENTISTS, RESULTING IN A LARGE TRANSLATIONAL RESEARCH PROGRAM
The Netherlands Cancer Institute (NKI) has been at the international forefront of cancer care and research for more than a century. The NKI is a Comprehensive Cancer Center, officially accredited by the OECI, combining a dedicated cancer hospital (Antoni van Leeuwenhoek ziekenhuis - AVL) and research institute (Het Nederlands Kanker Instituut - NKI) under one roof in an independent organization with one Board of Directors.
Combining health care and scientific research within the same institute offers a great, unique benefit for cancer patients. Specialized cancer care professionals work together daily in multidisciplinary teams to set up and carry out treatment plans tailored to the needs of individual patients, because no two tumors are alike. Cancer patients or patients referred for cancer diagnosis can come to our hospital, known as the Antoni van Leeuwenhoek, to make use of this personalised approach and the state-of-the-art research and treatment facilities.
The hospital has 180 beds, an outpatient clinic and a large radiotherapy department. Facilities for clinical research include a comprehensive patient database, a large collection of tumor samples with extensive clinical data, other biobanks, a data center for clinical studies, extensive diagnostic facilities, a pharmacy with a GMP-certified production unit for experimental drugs and biologicals, large patient cohorts, and active research groups in pharmacology, epidemiology and psychosocial oncology. The research institute has more than 650 active employees investigating many aspects of cancer development, diagnosis, treatment and epidemiology. Scientists at the Netherlands Cancer Institute have access to state-of-the-art research facilities supporting their basic, clinical and translational research.
Vall d’Hebron Institute of Oncology (VHIO)
VHIO COLLABORATES CLOSELY WITH THE VALL D’HEBRON UNIVERSITY HOSPITAL’S ONCOLOGY DEPARTMENT, DRIVEN BY A SHARED DETERMINATION TO BOTH ADVANCE AND ACCELERATE PERSONALIZED AND TARGETED THERAPIES AGAINST CANCER
Established in 2006, the Vall d´Hebron Institute of Oncology (VHIO) is a leading comprehensive cancer center of excellence where its scientists and research physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer. Undertaking one of Spain´s most dynamic cancer research programs, VHIO is dedicated to delivering on the promise of ´precision´ medicine in oncology – turning cancer discovery into more effective treatments and better practice for the care of our patients.
Research at VHIO is organised into four main programs—Preclinical, Translational, Clinical, and Core Technologies—VHIO´s team of some 200 researchers and physician-scientists focuses on understanding the fundamental biology of human cancer, from cellular and molecular biology and genetics to therapeutics.
The Preclinical and Translational Research Programs enhances the bench-to-bedside and bedside-to-bench principle, adopting a purely translational and multidisciplinary approach with the development of sophisticated research tools (i.e. xenograft models to mimic patient disease and to study tumor development in optimized research models). They translate advances in molecular research to patient care as rapidly as possible, tackling the disease from all possible angles and generating synergies between molecular and clinical research in oncology, playing a key role in the drug development process.
The Clinical Research Program, which incorporates multidisciplinary cancer taskforces, is dedicated to developing both novel agents directed to specific signaling pathways in cancer and new or redefined tools to diagnose cancer earlier and better predict response to treatment. Our researchers pioneer important studies involving both preclinical and early-drug development research studies and lead multiple phase I, II and III clinical trials designed to identify more effective cancer therapies tailored to individual patients. For the validation and interpretation of “omics”-based tests, medical oncologists and cancer biologists are provided with reliable data tools to investigate biomarkers that are being developed to optimize patient stratification based on differences in response patterns to cancer therapies or outcome.